Obesity Management Congress 2018
Medications for Obesity
Natural treatments for Obesity
Depression management and abuse recovery
Dietary Treatment for Obesity
The 27th World Congress on Diet, Nutrition and Obesity Conference 2018 going to be held at Auckland, New Zealand on the 7th and 8th of September 2018 is aimed to give an opportunity to the experts in the field of nutrition to examine the most recent progressions and difficulties in the field at the Obesity and Nutrition Meeting. Submit your research work abstract and register for the conference as a Speaker/Delegate now to avail Early Bird discounts on accommodation and registration and get published in Obesity and Nutrition Journals. To know more download the brochure for Diet Congress 2018.
Address: 47 Churchfield Road, London, W3 6AY
Contact person: Brooke Hendricks
Conference url: https://dietcongress.nutritionalconference.com/events-list/obesity-treatment-and-management
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Management Congress 2018 here
News-ID: 1057147 • Views: 1890
More Releases for Obesity
Anti-Obesity Drugs (Anti-obesity Medication) Market Will Generate Massive Revenu …
Latest survey on Anti-Obesity Drugs (Anti-obesity Medication) Market is conducted to provide hidden gems performance analysis of Anti-Obesity Drugs (Anti-obesity Medication) to better demonstrate competitive environment . The study is a mix of quantitative market stats and qualitative analytical information to uncover market size revenue breakdown by key business segments and end use applications. The report bridges the historical data from 2017 to 2022 and forecasted till 2027*, the outbreak
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle
Covid-19 pandemic fuels pet obesity.
Covid-19 pandemic fuels pet obesity. Fit4dogsuk, is currently helping dog owners in the East Yorkshire area during the Pandemic, with the weight loss challenge for their canine companions. As we have all been forced to change our habits during Covid 19, this has also had an effect on our dog’s. Their eating habits, activity levels and weight, have all changed and this can quickly affect their quality of life. A
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close
Obesity Treatment Market driven by rise in childhood obesity rates
Obesity is a disorder in which excess body fat gets accumulated to such extent that it may have negative effects on health. It occurs over time when people eat more calories than they utilize. The reasons for obesity can be medical problems, inactivity, genetics, family lifestyle, unhealthy diet, medications, age, and pregnancy. Being obese increases the risk of diabetes, heart disease, stroke, arthritis, and some type of cancers. Obesity treatment
Diabetes & Obesity Drug Development Pipeline Will Continue to Grow with the Risi …
"The Report Diabetes & Obesity Drug Development Pipeline Review, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these